在南非豪登省年轻女性中防范关于雷那卡帕韦的虚假信息(PROTECT-L) (PROTECT-L)
在南非豪登省年轻女性中防范关于来那卡帕韦的误导信息
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.
Primary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Teniola Egbe, MPH, MBE
- 电话号码:215-898-2939
- 邮箱:tegbe@pennmedicine.upenn.edu
研究联系人备份
- 姓名:Alison Buttenheim, PhD
- 邮箱:butt@nursing.upenn.edu
学习地点
-
-
-
Johannesburg、南非
- 招聘中
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
接触:
- Candice Chetty-Makkan, PhD
- 电话号码:+27 (0) 10 001 7941
- 邮箱:cchetty@heroza.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Female (cisgender or transgender)
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide consent
- Able to read and understand English
Exclusion Criteria:
Unwilling or unable to provide consent for study participation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
Participants enrolled in the control group will receive unrelated information on diabetes topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
|
其他:Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impendingLlenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending Lenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lenacapavir intention, at the end of the baseline assessment
大体时间:At the end of the baseline assessment
|
Intention to get the Lenacapavir, measured after inoculation intervention and misinformation exposure The intention to get Lenacapavir will be measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lenacapavir intention, follow-up
大体时间:2-4 weeks
|
Intention to get Lenacapavir, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Recommend to friends, at the end of the baseline assessment
大体时间:At the end of the baseline assessment
|
Intention to recommend Lenacapavir to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
At the end of the baseline assessment
|
|
Recommend to friends, follow-up
大体时间:2-4 weeks
|
Intention to recommend Lenacapavir to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action. |
2-4 weeks
|
|
Credibility of inoculated exposure #1
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #2
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #3
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #4
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #5
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #6
大体时间:At the end of the baseline assessment
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
At the end of the baseline assessment
|
|
Credibility of inoculated exposure #7,follow-up
大体时间:2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #8,follow-up
大体时间:2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim ,for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #9,follow-up
大体时间:2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Credibility of inoculated exposure #10,follow-up
大体时间:2-4 weeks
|
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #1
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #2
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #3
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #4
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #5
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #6
大体时间:At the end of the baseline assessment
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
At the end of the baseline assessment
|
|
Anxiousness of inoculated exposure #7,follow-up
大体时间:2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #8,follow-up
大体时间:2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #9,follow-up
大体时间:2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Anxiousness of inoculated exposure #10,follow-up
大体时间:2-4 weeks
|
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried. |
2-4 weeks
|
|
Shareability of inoculated exposure #1
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #2
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #3
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #4
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #5
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #6
大体时间:At the end of the baseline assessment
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of inoculated exposure #7,follow-up
大体时间:2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #8,follow-up
大体时间:2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #9,follow-up
大体时间:2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
|
Shareability of inoculated exposure #10,follow-up
大体时间:2-4 weeks
|
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim. |
2-4 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.